TherapeuticsMD (NASDAQ:TXMD)‘s stock had its “buy” rating restated by stock analysts at $1 in a research note issued on Tuesday. They currently have a $14.00 price target on the stock. $1’s price target would suggest a potential upside of 148.67% from the company’s previous close.
The analysts wrote, “TXMD provided an update on the Imvexxy launch and a competitor reported 4Q18 results yielding insights into VVA market dynamics and reimbursement. TXMD’s periodic Imvexxy launch updates provide valuable information in the absence of meaningful audited script data. We’re encouraged by several important metrics, including: 1) Imvexxy scripts grew 19% (month/month) in Jan to continue on a best-in-class trajectory, 2) based on Jan alone, Imvexxy still outpaces the most recent competitive launch from a quarterly perspective, 3) read-across from a recent competitive launch points to 60% achievability for net pricing, and 4) United Health is added to growing list of Imvexxy coverage. We remain optimistic about TXMD shares with 3 launches in 2019 described in our recent report. Maintain Outperform with details inside.””
Several other brokerages also recently commented on TXMD. Cantor Fitzgerald set a $27.00 target price on TherapeuticsMD and gave the company a “buy” rating in a report on Wednesday, November 7th. Zacks Investment Research raised TherapeuticsMD from a “hold” rating to a “buy” rating and set a $6.25 target price on the stock in a research report on Wednesday, October 17th. BidaskClub upgraded TherapeuticsMD from a “sell” rating to a “hold” rating in a report on Tuesday, February 5th. ValuEngine cut shares of TherapeuticsMD from a “buy” rating to a “hold” rating in a research report on Monday, October 29th. Finally, Oppenheimer set a $14.00 price objective on shares of TherapeuticsMD and gave the stock a “buy” rating in a report on Wednesday, November 7th. Three equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. TherapeuticsMD presently has an average rating of “Buy” and a consensus price target of $14.45.
In other news, insider John C.K. Iv Milligan sold 258,127 shares of the firm’s stock in a transaction dated Tuesday, December 18th. The stock was sold at an average price of $3.69, for a total value of $952,488.63. Following the completion of the sale, the insider now directly owns 1,601,419 shares in the company, valued at approximately $5,909,236.11. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Robert G. Finizio sold 184,910 shares of TherapeuticsMD stock in a transaction that occurred on Thursday, December 20th. The stock was sold at an average price of $3.66, for a total transaction of $676,770.60. Following the transaction, the chief executive officer now directly owns 18,458,559 shares in the company, valued at approximately $67,558,325.94. The disclosure for this sale can be found here. Insiders sold a total of 2,136,475 shares of company stock worth $9,706,083 in the last ninety days. Insiders own 22.85% of the company’s stock.
A number of hedge funds have recently added to or reduced their stakes in the stock. Geode Capital Management LLC raised its position in TherapeuticsMD by 9.0% in the fourth quarter. Geode Capital Management LLC now owns 2,206,185 shares of the company’s stock worth $8,405,000 after acquiring an additional 183,048 shares during the period. Stifel Financial Corp raised its position in TherapeuticsMD by 17.6% during the fourth quarter. Stifel Financial Corp now owns 2,437,688 shares of the company’s stock worth $9,329,000 after acquiring an additional 364,211 shares during the period. Great West Life Assurance Co. Can increased its position in TherapeuticsMD by 79.5% during the fourth quarter. Great West Life Assurance Co. Can now owns 28,183 shares of the company’s stock worth $103,000 after purchasing an additional 12,483 shares during the last quarter. Royce & Associates LP purchased a new position in shares of TherapeuticsMD in the fourth quarter valued at approximately $191,000. Finally, Bank of New York Mellon Corp raised its holdings in TherapeuticsMD by 0.7% during the fourth quarter. Bank of New York Mellon Corp now owns 30,499,363 shares of the company’s stock worth $116,202,000 after purchasing an additional 213,444 shares in the last quarter. 73.16% of the stock is owned by institutional investors.
TherapeuticsMD Company Profile
TherapeuticsMD, Inc operates as a women's health care product company. Its pipeline of hormone therapy drug candidates include TX-001HR, a combination of estradiol and progesterone drug candidate under clinical trials for the treatment of moderate to severe vasomotor symptoms due to menopause; TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil; and TX-004HR, an applicator-free vaginal estradiol softgel drug candidate for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy in post-menopausal women with vaginal linings that do not receive enough estrogen.
Featured Article: How to use beta for portfolio diversification
Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.